Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U.S. Phase I Clinical Study
September 27, 2017 17:08 ET
|
Helix BioPharma Corp.
RICHMOND HILL, ONTARIO--(Marketwired - Sept. 27, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing...
Helix Biopharma Corp. Closes Private Placement
August 31, 2017 16:35 ET
|
Helix BioPharma Corp.
RICHMOND HILL, ONTARIO--(Marketwired - Aug. 31, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug...
Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal
August 22, 2017 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, ONTARIO--(Marketwired - Aug. 22, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing...
Helix Biopharma Corp. to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
July 31, 2017 16:33 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - July 31, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug...
Helix BioPharma Corp. Initiates Enrollment in the Third Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
July 25, 2017 16:30 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - July 25, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug...
Helix BioPharma Corp. and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade
July 18, 2017 17:01 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - July 18, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug...
Helix BioPharma Corp. Director Resigns
July 17, 2017 07:00 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - July 17, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug...
Helix BioPharma Corp. Announces Collaboration with Moffitt Cancer Center
July 11, 2017 07:00 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - July 11, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug...
Helix BioPharma Corp. Announces Fiscal Third Quarter 2017 Results
June 13, 2017 17:49 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - June 13, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative...
Helix BioPharma Corp. Closes Private Placement
June 07, 2017 19:19 ET
|
Helix BioPharma Corp.
TORONTO, ONTARIO--(Marketwired - June 7, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates...